Advertisement

Topics

Bayer Announces New Analyses for Vitrakvi in TRK Fusion Cancer with Solid Tumors and New Data in Primary CNS Tumors and Brain Metastases

10:55 EDT 16 May 2019 | Speciality Pharma Journal

WHIPPANY, N.J., May 15, 2019 /PRNewswire/ — Bayer today announced findings from new analyses and data for Vitrakvi® (larotrectinib), which is approved for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic tropomyosin receptor kinase (NTRK) gene fusion without a known acquired resistance mutation that are either metastatic or where …

Original Article: Bayer Announces New Analyses for Vitrakvi in TRK Fusion Cancer with Solid Tumors and New Data in Primary CNS Tumors and Brain Metastases

NEXT ARTICLE

More From BioPortfolio on "Bayer Announces New Analyses for Vitrakvi in TRK Fusion Cancer with Solid Tumors and New Data in Primary CNS Tumors and Brain Metastases"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Pediatrics
Pediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...